Stock’s Earning Overview for Graco Inc.(NYSE:GGG): Dicerna Pharmaceuticals, Inc.(NASDAQ:DRNA)

0
1

Graco Inc. (GGG) will report its next earnings on Oct 23 AMC. The company reported the earnings of $0.45/Share in the last quarter where the estimated EPS by analysts was $0.51/share. The difference between the expected and actual EPS was $-0.06/share, which represents an Earnings surprise of -11.8%.

Many analysts are providing their Estimated Earnings analysis for Graco Inc. and for the current quarter 9 analysts have projected that the stock could give an Average Earnings estimate of $0.39/share. These analysts have also projected a Low Estimate of $0.38/share and a High Estimate of $0.41/share.

In case of Revenue Estimates, 9 analysts have provided their consensus Average Revenue Estimates for Graco Inc. as 392.62 Million. According to these analysts, the Low Revenue Estimate for Graco Inc. is 388.5 Million and the High Revenue Estimate is 397.86 Million. The company had Year Ago Sales of 406.44 Million.

These analysts also forecasted Growth Estimates for the Current Quarter for GGG to be -9.3%. They are projecting Next Quarter growth of -4.26%. For the next 5 years, Graco Inc. is expecting Growth of 3% per annum, whereas in the past 5 years the growth was -3.72% per annum.

Some buy side analysts are also providing their Analysis on Graco Inc., where 0 analysts have rated the stock as Strong buy, 0 analysts have given a Buy signal, 4 said it’s a HOLD, and 0 analysts rated the stock as Sell. (These Recommendations are for the Current Month Only reported by Yahoo Finance.)

When it comes to the Analysis of a Stock, Price Target plays a vital role. Analysts reported that the Price Target for Graco Inc. might touch $48 high while the Average Price Target and Low price Target is $45.4 and $43 respectively.

Graco Inc. closed its last trading session at $46.55 with the gain of 0.45%. The Market Capitalization of the company stands at 7.8 Billion. The Company has 52-week high of $53.91 and 52-week low of $38.59. The stock’s current distance from 20-Day Simple Moving Average (SMA20) is 1.67% where SMA50 and SMA200 are 2.26% and -2.2% respectively. The Company Touched its 52-Week High on 04/24/19 and 52-Week Low on 12/24/18.

The Relative Volume of the company is 0.79 and Average Volume (3 months) is 451.58 million. The company’s P/E (price to earnings) ratio is 24.09 and Forward P/E ratio of 24.78.

The company shows its Return on Assets (ROA) value of 21.1%. The Return on Equity (ROE) value stands at 38%. While it’s Return on Investment (ROI) value is 35.6%.

While looking at the Stock’s Performance, Graco Inc. currently shows a Weekly Performance of 3.45%, where Monthly Performance is 5.82%, Quarterly performance is 0.6%, 6 Months performance is -9.04% and yearly performance percentage is 10.96%. Year to Date performance value (YTD perf) value is 11.73%. The Stock currently has a Weekly Volatility of 1.24% and Monthly Volatility of 1.55%.

Dicerna Pharmaceuticals, Inc. (DRNA) will report its next earnings on Nov 07 AMC. The company reported the earnings of $-0.45/Share in the last quarter where the estimated EPS by analysts was $-0.28/share. The difference between the expected and actual EPS was $-0.17/share, which represents an Earnings surprise of -60.7%.

Many analysts are providing their Estimated Earnings analysis for Dicerna Pharmaceuticals, Inc. and for the current quarter 9 analysts have projected that the stock could give an Average Earnings estimate of $0.05/share. These analysts have also projected a Low Estimate of $-0.4/share and a High Estimate of $2.83/share.

In case of Revenue Estimates, 8 analysts have provided their consensus Average Revenue Estimates for Dicerna Pharmaceuticals, Inc. as 38.04 Million. According to these analysts, the Low Revenue Estimate for Dicerna Pharmaceuticals, Inc. is 4 Million and the High Revenue Estimate is 212.9 Million. The company had Year Ago Sales of 1.54 Million.

These analysts also forecasted Growth Estimates for the Current Quarter for DRNA to be 14.3%. They are projecting Next Quarter growth of -6.9%. For the next 5 years, Dicerna Pharmaceuticals, Inc. is expecting Growth of 18.21% per annum, whereas in the past 5 years the growth was 13.13% per annum.

Some buy side analysts are also providing their Analysis on Dicerna Pharmaceuticals, Inc., where 1 analysts have rated the stock as Strong buy, 0 analysts have given a Buy signal, 0 said it’s a HOLD, and 0 analysts rated the stock as Sell. (These Recommendations are for the Current Month Only reported by Yahoo Finance.)

When it comes to the Analysis of a Stock, Price Target plays a vital role. Analysts reported that the Price Target for Dicerna Pharmaceuticals, Inc. might touch $27 high while the Average Price Target and Low price Target is $23.13 and $20 respectively.

Dicerna Pharmaceuticals, Inc. closed its last trading session at $17.3 with the gain of 1.73%. The Market Capitalization of the company stands at 1.15 Billion. The Company has 52-week high of $18.39 and 52-week low of $9.31. The stock’s current distance from 20-Day Simple Moving Average (SMA20) is 9.73% where SMA50 and SMA200 are 17.06% and 29.15% respectively. The Company Touched its 52-Week High on 10/31/19 and 52-Week Low on 12/24/18.

The Relative Volume of the company is 0.8 and Average Volume (3 months) is 466.66 million. The company’s P/E (price to earnings) ratio is 0 and Forward P/E ratio of 0.

The company shows its Return on Assets (ROA) value of -26.2%. The Return on Equity (ROE) value stands at -50.3%. While it’s Return on Investment (ROI) value is -45%.

While looking at the Stock’s Performance, Dicerna Pharmaceuticals, Inc. currently shows a Weekly Performance of 6.73%, where Monthly Performance is 23.68%, Quarterly performance is 29.51%, 6 Months performance is 54.52% and yearly performance percentage is 22.65%. Year to Date performance value (YTD perf) value is 64.64%. The Stock currently has a Weekly Volatility of 3.83% and Monthly Volatility of 4.41%.

SHARE